IQuity Lands NIH Grant To Help Identify Alzheimer's Early

The $320k grant will support research that builds on IQuity’s autoimmune diagnostic expertise and new data analytics platform. The company believes the emerging therapies for Alzheimer's will be most effective if they are used to treat the disease early in its progression.

MT1810_Synapse_1050113234_1200.jpg
A rendering of synapse destruction in neurodegenerative disease • Source: shutterstock.com

IQuity Labs Inc.'s plan to apply its new machine learning-based data mining and analytics platform to the early detection of Alzheimer's disease has earned the endorsement of the US National Institutes of Health. In September, NIH's National Institute on Aging (NIA) awarded the company a $320,000 supplemental grant to help get the project going.

"This is the foundation. This is the first set of building blocks that we're going to put on the board to go after this problem," iQuity CEO Chase Spurlock told Medtech Insight. "We're very humbled by the NIH's support

More from Clinical Trials

More from R&D